{"schema_version":"secwatch.filing_event.v1","accession":"0001730463-26-000012","form_type":"8-K","ticker":"AUTL","cik":"0001730463","company_name":"Autolus Therapeutics plc","filed_at":"2026-01-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.024800+00:00","generated_at":"2026-05-16T10:54:21.783748+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Autolus reports preliminary 2025 AUCATZYL rev $75M; guides FY2026 $120-135M","bullets":["Preliminary unaudited AUCATZYL net product revenue: Q4 2025 ~$24M, full year 2025 ~$75M.","FY 2026 revenue guidance $120M-$135M; expects positive gross margin in 2026.","Cash runway extended into Q4 2027 based on current operating plans.","Pipeline: obe-cel Phase 2 CATULUS (pediatric B-ALL) and LUMINA (lupus nephritis) enrolling; BOBCAT (MS) and AUTO8 (AL amyloidosis) first patients dosed.","UK commercial launch under NICE approval; manufacturing cost reduction initiatives underway."],"urls":{"canonical":"https://secwatch.observer/filing/0001730463-26-000012","json":"https://secwatch.observer/filing/0001730463-26-000012.json","markdown":"https://secwatch.observer/filing/0001730463-26-000012.md","text":"https://secwatch.observer/filing/0001730463-26-000012.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1730463/000173046326000012/0001730463-26-000012-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1730463/000173046326000012/autl-20260112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T10:54:21.783748+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}